Literature DB >> 12734900

High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation.

Olivier Lambotte1, Patrice Cacoub, Nathalie Costedoat, Gisele Le Moel, Zahir Amoura, Jean-Charles Piette.   

Abstract

OBJECTIVE: A high serum ferritin concentration with a low percentage of glycosylated ferritin (< 20%) have been reported to be a specific marker of active adult Still's disease (ASD). However, high ferritin levels are found during hemophagocytosis syndrome (HS). We investigated the ferritin level and the percentage of glycosylation in a HS series of various causes.
METHODS: Diagnosis of HS was confirmed by erythrophagocytosis pictures on a bone marrow cytology or biopsy in all patients. Serum ferritin concentration was determined on a heterogenous immunoassay module. Glycosylated ferritin was separated using concanavalin A (Con-A) sepharose 4B chromatography. The nonglycosylated ferritin unbound to Con-A was recovered in the supernatant and quantified with the same procedure. Percentages of glycosylated ferritin less than 20% are considered to be usual in ASD, between 20 and 40% usual in inflammatory syndrome, and between 50 and 80% normal.
RESULTS: In all cases tested during the acute phase of the disease, ferritin blood level was high and the percentage of glycosylated ferritin was low, less than 20%.
CONCLUSION: The combination of high ferritin level and low percentage of glycosylation may be a marker of excessive macrophage activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734900

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  18 in total

1.  Pyrexia and a rash.

Authors:  Renee Hoenderkamp; Kirun Gunganah; Tahseen A Chowdhury
Journal:  Clin Med (Lond)       Date:  2012-02       Impact factor: 2.659

2.  Decoupling ferritin synthesis from free cytosolic iron results in ferritin secretion.

Authors:  Ivana De Domenico; Michael B Vaughn; Prasad N Paradkar; Eric Lo; Diane M Ward; Jerry Kaplan
Journal:  Cell Metab       Date:  2011-01-05       Impact factor: 27.287

Review 3.  Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature.

Authors:  J-B Arlet; Thi Huong D Le; A Marinho; Z Amoura; B Wechsler; T Papo; J-C Piette
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

Review 4.  A possible role for secreted ferritin in tissue iron distribution.

Authors:  Esther G Meyron-Holtz; Shirly Moshe-Belizowski; Lyora A Cohen
Journal:  J Neural Transm (Vienna)       Date:  2011-02-06       Impact factor: 3.575

5.  Glycosylated ferritin as an improved marker for post-transfusion iron overload.

Authors:  Ayako Ishihara; Tsuyuko Yamauchi; Katsuyoshi Ikeda; Yoko Fukuyoshi; Toshiro Yokoyama; Yuji Yonemura; Mitsuhiro Uchiba; Hirotaka Matsui
Journal:  Int J Hematol       Date:  2021-01-05       Impact factor: 2.490

Review 6.  Hyperferritinemia and inflammation.

Authors:  Kate F Kernan; Joseph A Carcillo
Journal:  Int Immunol       Date:  2017-11-01       Impact factor: 4.823

7.  Hemophagocytic syndrome secondary to adult-onset Still's disease but very similar to lymphoma.

Authors:  Xin-Hua Zhang; Yong-Mei Han; Wen-Wen Wang; Hao Cheng; Ke-Jian Zhu
Journal:  Int J Clin Exp Pathol       Date:  2012-04-16

8.  Correlation of serum CX3CL1 level with disease activity in adult-onset Still's disease and significant involvement in hemophagocytic syndrome.

Authors:  Tsuyoshi Kasama; Hidekazu Furuya; Ryo Yanai; Kumiko Ohtsuka; Ryo Takahashi; Nobuyuki Yajima; Yusuke Miwa; Kazuo Kobayashi
Journal:  Clin Rheumatol       Date:  2012-02-10       Impact factor: 2.980

9.  A Case of Delayed COVID-19-Related Macrophage Activation Syndrome.

Authors:  Abdelnassir Abdelgabar; Mohammed Elsayed
Journal:  J Med Cases       Date:  2022-04-12

10.  A rare trigger for macrophage activation syndrome.

Authors:  Shikhar Agarwal; Jayavani Moodley; Gati Ajani Goel; Karl S Theil; Syed S Mahmood; Richard S Lang
Journal:  Rheumatol Int       Date:  2009-10-16       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.